Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Drug: Ivonescimab · 1 trial · 1 indication
Progression-free survival (PFS) assessed by IRRC per RECIST v1.1
| Arm | Type | Description |
|---|---|---|
| Arm A: Ivonescimab in combination with mFOLFOX6 | EXPERIMENTAL | Subjects will receive Ivonescimab Plus mFOLFOX6 via intravenous infusion (IV) Q2W, up to 8 cycles. Afterward, Ivonescimab plus Leucovorin and 5-FU will be used for maintenance treatment (administered on Day 1 of each cycle, Q2W) up to 2 years. |
| Arm B: Bevacizumab in combination with mFOLFOX6 | ACTIVE_COMPARATOR | Subjects will receive bevacizumab Plus mFOLFOX6 (Oxaliplatin, Leucovorin and 5-Fluorouracil) via intravenous infusion (IV) Q2W, up to 8 cycles in treatment periods per the randomization schedule. Afterward, bevacizumab Plus 5-FU and Leucovorin will be used for maintenance treatment (administered on Day 1 of each cycle, Q2W) up to 2 years. |
| Name | Type | Description |
|---|---|---|
| Drug: Ivonescimab Injection | DRUG | Subjects will receive Ivonescimab Plus mFOLFOX6 (Oxaliplatin, Leucovorin and 5-Fluorouracil) via intravenous infusion (IV) Q2W, up to 8 cycles. Afterward, Ivonescimab plus Leucovorin and 5-Fluorouracil will be used for maintenance treatment (administered on Day 1 of each cycle, Q2W) for up to 2 years. |
| Drug: Bevacizumab Injection | DRUG | Subjects will receive bevacizumab Plus mFOLFOX6 (Oxaliplatin, Leucovorin and 5-Fluorouracil) via intravenous infusion (IV) Q2W, up to 8 cycles in treatment periods per the randomization schedule. Afterward, bevacizumab Plus 5-FU and Leucovorin will be used for maintenance treatment (administered on Day 1 of each cycle, Q2W) up to 2 years. |
Inclusion Criteria: 1. ECOG performance status score of 0 or 1 2. Expected life expectancy ≥ 6 months 3. Patients with histologically or cytologically confirmed metastatic CRC 4. No prior systemic therapy for metastatic CRC 5. At least 1 measurable noncerebral lesion Exclusion Criteria: 1. Micros...
Top 20 of 76 competitors
Ivonescimab is an investigational small molecule being studied for the treatment of metastatic colorectal cancer (CRC). It is currently in Phase 3 clinical development and is not yet approved by regulatory authorities.
Ivonescimab is being developed by Summit Therapeutics Inc., a biopharmaceutical company traded on the stock exchange under the ticker symbol SMMT.
Ivonescimab is currently in Phase 3 clinical development. It is an investigational drug and has not been approved by the FDA or any other regulatory agency.
Ivonescimab is being evaluated in a Phase 3 clinical trial with the identifier NCT07228832. This randomized, double-blind, active-controlled study is recruiting 600 patients with metastatic colorectal cancer and is being conducted across multiple countries including the United States, Belgium, Canada, and Japan.
Yes, Ivonescimab is also known as Ivonescimab Injection. Both names refer to the same investigational drug being developed for metastatic colorectal cancer.